Dear Duchenne community,
We at Roche and our U.S. affiliate Genentech are privileged to take on development of BMS-986089. Moving forward this investigational molecule will be called RG6206. Our team is looking forward to partnering with the Duchenne community to make a meaningful difference to young people with Duchenne.
Our immediate priority is to ensure a seamless transition of the development programme. To achieve this we are working in close partnership with BMS. The phase 2/3 study of RG6206 in ambulatory boys with Duchenne is actively recruiting in the US and five boys have been dosed to date.
We assure you there will be no impact on participants in the study during the transition from BMS to Roche. We are working closely with the study sites to ensure that study participants have all the information they need to continue participation without interruption.
The following US study sites are currently open for recruitment:
Neuromuscular Research Center, Arizona
David Geffen School of Medicine UCLA, California
University of Florida, Florida
Kennedy Krieger Institute, Maryland
Planned US sites include:
Stanford University, California
University of Kansas Medical Center, Kansas
Saint Louis Children's Hospital, Missouri
University of California Davis Medical Center, California
Cincinnati Children's Hospital Medical Center, Ohio
Nemours Children's Hospital, Florida
Rush University Medical Center, Illinois
University of Iowa, Iowa
Children's Hospital of Philadelphia, Pennsylvania
Seattle Children's Hospital – Washington
Center for Integrative Rare Disease Research (CIRDR), Georgia
Las Vegas Clinic, Nevada
Nationwide Children's Hospital, Ohio
Yale University School of Medicine, Connecticut
Additional countries planned for 2017 and 2018 (pending Regulatory and Ethics approvals) include:
Argentina, Australia, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Spain, Sweden and United Kingdom.
We would like to thank all the boys and families who consider taking part in clinical studies; your commitment is helping to advance research in Duchenne.
We look forward to working together with the Duchenne community and sharing more updates about RG6206 in the future.
If you have any questions or would like to discuss this, please reach out to me at email@example.com Best regards,
Sangeeta Jethwa, MD, on behalf of the Roche Duchenne Muscular Dystrophy team Head, Patient Partnership, Rare Diseases